No Permanent Implant

The Senella® Scaffolds will be formed out of a biocompatible and absorbable polymer that is FDA-approved and CE-marked for a variety of other clinical applications. Multiple Preclinical Studies have shown that the scaffolds slowly get absorbed by the body while the patient's own tissue forms synchronously. After the scaffold has been fully resorbed, the preclinical trials show that the end-result is natural breast tissue with no foreign body remnants.

Degradation Behaviour of BellaSeno implants

Natural Tissue

Our Scaffolds will aim to guide the growth of natural tissue with the use of patient's own body fat harvested via routinely practiced liposuction procedure.

Anticipated Key Benefits:

  • Tissue is regenerated from the patient's own body-fat, without the use of isolated/cultivated stem cells or animal-derived products - may help avoid risk of rejection, chronic infection and capsular contracture associated with current standard of care.
  • No foreign material is permanently implanted in the body, so long-term medication may no longer be needed.
  • Risk of repeated surgeries may be reduced.

Fat Injection

Interested in transforming your Additive Manufacturing using our technology?

BellaMake by BellaSeno offers the use of Design and Additive Manufacturing expertise of BellaSeno's breakthrough Senella® technology platform to create:

  1. A wide spectrum of 3D Cell Culture Meshes and Custom Scaffolds for drug screening and research use.
  2. CMO services for medical devices.

These services can be used for:

  • Tissue Engineering and Cancer Research.
  • Medical Device Manufacturing.
  • Drug Screening

Project Concept


The Senella® technology is a product of more than 10 years of rigorous product development and preclinical studies. Publications cited below refer to the Biocompatibility and Efficacy of Senella® devices within Preclinical Studies

Our Founding and Management Team

BellaSeno Founding and Management team comprises experts from diverse fields ranging from biomedical engineering, Additive Manufacturing, Plastic Surgery, Medical Imaging and Polymer Development.

Mohit P. Chhaya, PhD
Chief Executive Officer

Mohit P Chhaya, PhD

Dr. Mohit Chhaya is a co-founder and CEO of BellaSeno GmbH and has over 10 years’ experience in Biomedical Engineering and Additive Manufacturing Technologies. Dr. Chhaya was instrumental in raising a total of >EUR 7 million of private and public financing and successfully brought BellaSeno from its initial conception to full ISO 13485-certification within 2 years. Dr. Chhaya also directed the development of BellaSeno’s preclinical as well as clinical validation and regulatory strategy. In this role, Dr. Chhaya has successfully delivered multi-partner industrial projects with value >EUR 3 million and successfully launched one of world’s first CMO service focused on resorbable implants made using Additive Manufacturing.

Dr. Chhaya has been named a co-inventor in 6 patents, was named an MIT Technology Review’s Innovator Under 35 for his achievements in the MedTech industry, one of the products developed under Dr. Chhaya’s leadership was awarded the highly prestigious Edison Award in 2020 and Dr. Chhaya has won >3 Young Achievement Australia entrepreneur awards for his work in pioneering social media analytics in 2008.

In prior roles, Dr. Chhaya worked as a Post-Doctoral Researcher at Technical University of Munich (TUM) - where he was part of a team that got awarded an Exist Research Translation grant by the German government. As part of duties, Dr. Chhaya shaped the global regulatory strategy for innovative scaffolds for lymph-node regeneration. Dr. Chhaya also worked as a Data Analyst at Moody’s Analytics for 2.5 years which gives Dr. Chhaya a broad knowledge of capital and derivatives markets.

Simon Champ, PhD, MBA
Supervisory Board Member

Simon Champ, PhD

Dr. Champ has held a variety of management positions in R&D, marketing and business development in the chemical industry. Dr. Champ’s MBA thesis focused on the commercialisation of regenerative medicine technologies. Dr. Champ is co-founder of Progensis UG (haftungsbeschränkt), a boutique consultancy focusing on the regenerative medicine industry. BellaSeno benefits from Dr. Champ’s experience in business strategy, marketing and venture valuation, as well as his international network of commercially relevant contacts.

Dietmar W. Hutmacher, PhD, MBA

DProf Dietmar W. Hutmacher, PhD, MBA

Distinguished Prof Hutmacher is a biomedical engineer, an educator, an inventor, and a creator of new intellectual property opportunities. DProf Hutmacher is an internationally recognized leader in the fields of biomaterials, tissue engineering &regenerative medicine. He has translated a bone tissue engineering concept from the laboratory through to clinical application and ultimately FDA&CEMark clearance. More than 20000 patients have been treated with the FDA-cleared Polycaprolactone-based bone engineering scaffolds developed by Osteopore.
DProf Hutmacher is listed as one of the top 50 biomedical researchers in the world and a co-founder of Osteopore International. His most recent research efforts in applying additive biomanufacturing to scaffold-guided breast reconstruction have resulted in traditional scientific/academic outputs as well as pivotal commercialisation outcome.

Jan-Thorsten Schantz, MD, PhD
Clinical Advisor

Jan-Thorsten Schantz, MD, PhD

Until a tragic strike of fate left him severely incapacitated in early 2017, PD Dr. med. habil. Schantz was a world-leading clinician scientist in the area of tissue engineering & regenerative medicine. He had over 20 years of clinical experience in the field of plastic and reconstructive surgery, specifically in breast reconstructions and bone defects. PD Dr. Schantz is a co-founder of Osteopore, and his scientific and clinical work was pivotal for the regulatory approval of polycaprolactone-based bone scaffolds via the FDA 510(k) and CE certification pathways. PD Dr. Schantz wrote his medical doctoral thesis at Freiburg University, obtained his PhD at the National University of Singapore and his Habilitation in the field of tissue engineering/bone regeneration at TUM. His pre-eminent international standing and impact on the field is illustrated by his excellent publication record.
Until the abrupt end of his career due to permanent disability, PD Dr. Schantz also served as editor of the World Scientific book series 'Manuals in Biomedical Research' (since 2004), Visiting Associate Professor at Singapore's NTU School of Chemical and Biomedical Engineering (since 2013) and Acting Director of Clinical Research in Plastic and Reconstructive Surgery at Munich's Klinikum Rechts der Isar (since 2016).

Paul Severin Wiggenhauser, MD
Clinical Advisor

Paul Severin Wiggenhauser, MD

Dr. Wiggenhauser brings plastic surgical experience to BellaSeno through his residency in Plastic Surgery at Ludwig-Maximillian Universität München (Germany) and has dedicated his scientific work towards innovative CAD/CAM technologies and adipose derived stem cells to improve surgical techniques.
Dr. Wiggenhauser's thesis on Breast Tissue Engineering was awarded the Henner Graeff Preis for Best Thesis in Translational Research at Technische Universität München (Germany) in 2014. During his time at Ulm University Medical Centre, he has improved his analytical skills, strengthened his team work capacity and gained experience in management as vice coordinator of the central operation theatre at the Department of Oto-Rhino-Laryngology, Head and Neck Surgery. In 2017, he established a laboratory for stem cell research at Ludwig-Maximillian Universität München.
As deputy laboratory manager he focused on adipose tissue derived stem cells and translational research in plastic surgery. Moreover he investigated the application of 3D printing and polycaprolactone-based implants in reconstructive surgery. BellaSeno benefits from his experience in translational research in the field of plastic and reconstructive surgery. With his insight into daily clinical work, BellaSeno is able to optimize customer driven research and to improve implants with surgical insight.

Holger Buck, Dr.Jur

Holger Buck, Dr.Jur

Prof Buck serves as W3-Professor of International and German Business Law at a German University of Applied Sciences. He is member of the Scientific Committee of European Academy Otzenhausen and liaison professor of Heinrich Böll foundation. After having studied in Freiburg, Geneva and Strasbourg and after having graduated from Freiburg University he started his career as a lawyer while performing pro bono service as honorary judge (Anwaltsgericht). Prof. Buck works on international, EU and German competition law, sales law, company law as well as law of Intellectual Property. In recent years he has researched at University of Technology Sydney, University of British Columbia and University of Cape Town.

Our Investors and Funding Sources

BellaSeno has raised significant investments from a combination of private equity one of Germany’s top bioentrepreneurs as well as public grants from the Saxony Development Bank (SAB) and the European Fund for Regional Development (EFRE).

Herbert Stadler, PhD
Series A+B Investor

Herbert Stadler, PhD

Dr. Herbert Stadler is one of Europe's most successful serial bioentrepreneurs. Dr. Stadler has founded or co founded more than 10 companies including Stage Cell Therapies, IBA GmbH, Biometra GmbH, Ribonetics GmbH, HepaVec AG, IBA GmbH and DeveloGen AG. Dr. Stadler has successfully exited several startups - with the last exit being Stage GmbH sold to Juno/Celgene, now BMS.
Dr. Stadler obtained his Ph.D. at the Freie University of Berlin, obtained his postdoctoral lecture qualification ("Habilitation") at the University of Göttingen and headed the Molecular Neurobiology Group at the Max-Planck Institute of Biophysical Chemistry in Göttingen. He currently serves on the supervisory boards of BellaSeno GmbH, DeveloGen AG and IBA GmbH. .

Sächsische Aufbaubank

Our Technology in the Media

The Senella® technology has been showcased multiple times in the media around the world.


Press Releases

Keep up to date with our company and technology.

Get in touch